Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 9Phase 3 4Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 15Thoracic 10Other hematologic neoplasm 4CNS 4Other solid neoplasm 3Tumor-Agnostic 2Myeloid 2Lymphoid 2Classical hematology 2Sarcoma 1Plasma cell 1Endocrine 1

Conditions

Sarcoma, Ewing 1Sarcoma, Clear Cell 1Myoepithelioma 1Liposarcoma, Myxoid 1Histiocytoma, Angiomatoid Fibrous 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma, Extraskeletal Myxoid 1

Interventions

Temozolomide 33Radiotherapy 32pembrolizumab 18Cyclophosphamide 18Irinotecan 16Gemcitabine 16Doxorubicin 16Nivolumab 11Docetaxel 11Sirolimus 10Imatinib Mesylate 10Ifosfamide 10Filgrastim 10Radiation 9Bevacizumab 9Vincristine 8Carboplatin 8pazopanib 7Everolimus 7temsirolimus 6atezolizumab 6Peripheral Blood Stem Cell Transplantation 6Etoposide 6fludarabine phosphate 5Vorinostat 5Specimen Handling 5Radiotherapy, Conformal 5PM 01183 5Ipilimumab 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Topotecan × Sarcoma × Clear all
NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡